Strongbridge Biopharma plc Announces Positive Top-Line Results from the Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome

Press release originally posted on Strongbridgebio.com

~ SONICS Study Met Primary Endpoint with RECORLEV Demonstrating a Statistically Significant Normalization Rate of Urinary Free Cortisol at Six Months ~

~ Key Secondary Endpoints Evaluating Cardiovascular Risk Markers Showed Statistically Significant and Clinically Meaningful Improvements from Baseline ~

~ RECORLEV was Generally Well Tolerated with Only 3.2 Percent of Patients Demonstrating an Increase in Alanine Aminotransferase Measurement of Greater Than Five Times the Upper Limit of Normal~

~ Strongbridge Plans to Discuss Potential for Accelerated Approval of RECORLEV with FDA ~

DUBLIN, Ireland and TREVOSE, Pa., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced top-line results from the multinational, pivotal Phase 3 SONICS study evaluating RECORLEV™ (levoketoconazole) for the treatment of endogenous Cushing’s syndrome.

Continue Reading

Print

India Curbs Sale of Pharmaceutical Oxytocin After Abuse of Children

India is restricting the production and sale of a pharmaceutical version of oxytocin after criminals were found to be using it to induce puberty in victims of the child sex trade. Other abuses included using oxytocin to encourage extra milk production in cows, inducing childbirth, and improving growth in fruits and vegetables. Read more here:
https://www.tribuneindia.com/news/nation/ban-on-growth-drug-oxytocin-comes-into-effect-from-july-1/611773.html

Print

More Articles ...

Available Now!

PPRG6-500 Cover
The Pituitary Patient Resource Guide Sixth Edition is now available! Be one of the first to have the most up-to-date information. The Pituitary Patient Resource Guide a one of a kind publication intended as an invaluable source of information not only for patients but also their families, physicians, and all health care providers. It contains information on symptoms, proper testing, how to get a diagnosis, and the treatment options that are available. It also includes Pituitary Network Association's patient resource listings for expert medical care.

Buy Now